Share Market Newspaper

Crohn’s Disease Pipeline, Clinical Trials Assessment, and NDA Approvals 2023 (Updated)

 Breaking News
  • No posts were found

Crohn’s Disease Pipeline, Clinical Trials Assessment, and NDA Approvals 2023 (Updated)

September 15
19:34 2023
Crohn’s Disease Pipeline, Clinical Trials Assessment, and NDA Approvals 2023 (Updated)

DelveInsight’s, “Crohn’s Disease Pipeline Insight, 2023,” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn’s Disease pipeline landscape. It covers the Crohn’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Crohn’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Crohn’s Disease Pipeline Report

  • DelveInsight’s Crohn’s Disease report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for Crohn’s Disease treatment.
  • The leading companies working in the Crohn’s Disease Market include Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, SLA Pharma, HAV Vaccines Ltd, Enzo Biochem Inc., VHsquared Ltd., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Provention Bio, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Janssen, Protagonist Therapeutics, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, and others.
  • Promising Crohn’s Disease Pipeline Therapies in the various stages of development include Etrasimod, infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CP-461, Natalizumab, Adalimumab, Visilizumab, Methoxsalen +ECP, Darvadstrocel, and others.
  • May 2023, Takeda announced a study of Phase 4 Clinical Trials for Darvadstrocel. The main aim is to check the long term side effects of a repeat treatment of darvadstrocel and to see if that treatment improves symptoms of Crohn’s disease and complex perianal fistula. Participants will attend 8 clinic visits and will receive 1 treatment of darvadstrocel at the third visit. A magnetic resonance imaging (MRI) will be performed several times during the study.
  • September 2023: Pfizer announced a study of Phase 3 Clinical Trials for Etrasimod. This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn’s disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics).

 

Request a sample and discover the recent advances in Crohn’s Disease Treatment Drugs @ Crohn’s Disease Pipeline Report

 

The Crohn’s Disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Crohn’s Disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Crohn’s Disease clinical trial landscape.

 

Crohn’s Disease Overview

Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract, where inflammation extends all the way through the intestinal wall from mucosa to serosa. It is a relapsing and remitting disease.

 

Find out more about Crohn’s Disease Treatment Drugs @ Drugs for Crohn’s Disease Treatment

 

Crohn’s Disease Emerging Drugs Profile

  • Guselkumab: Janssen
  • RHB-104: RedHill Biopharma

 

Crohn’s Disease Pipeline Therapeutics Assessment

There are approx. 90+ key companies which are developing the therapies for Crohn’s Disease. The Crohn’s Disease companies which have their Crohn’s Disease drug candidates in the most advanced stage, i.e. Phase III include, Janseen.

 

Learn more about the emerging Crohn’s Disease Pipeline Therapies @ Crohn’s Disease Clinical Trials Assessment

 

Scope of the Crohn’s Disease Pipeline Report

  • Coverage- Global
  • Allergic Conjunctivitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Allergic Conjunctivitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Companies- Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, SLA Pharma, HAV Vaccines Ltd, Enzo Biochem Inc., VHsquared Ltd., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Provention Bio, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Janssen, Protagonist Therapeutics, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, and others.
  • Pipeline Therapies- Etrasimod, infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CP-461, Natalizumab, Adalimumab, Visilizumab, Methoxsalen +ECP, Darvadstrocel, and others.

 

Dive deep into rich insights for new drugs for Crohn’s Disease Treatment, Visit @ Crohn’s Disease Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Crohn’s Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Crohn’s Disease – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Crohn’s Disease Collaboration Deals
  9. Late Stage Products (Registered)
  10. Infliximab biosimilar: Amgen
  11. Drug profiles in the detailed report…..
  12. Late Stage Products (Phase III)
  13. Guselkumab: Janssen
  14. Drug profiles in the detailed report…..
  15. Mid Stage Products (Phase II/III)
  16. ABX464: Pfizer
  17. Drug profiles in the detailed report…..
  18. Mid Stage Products (Phase II)
  19. Mocravimod: Priothera
  20. Drug profiles in the detailed report…..
  21. Early Stage Products (Phase I)
  22. IMU-856: Immunic
  23. Drug profiles in the detailed report…..
  24. Preclinical Stage Products
  25. INV-88: Innovimmune Biotherapeutics
  26. Drug profiles in the detailed report…..
  27. Discovery Stage Products
  28. DNL975: Denali Therapeutics
  29. Inactive Products
  30. Crohn’s Disease Key Companies
  31. Crohn’s Disease Key Products
  32. Crohn’s Disease- Unmet Needs
  33. Crohn’s Disease- Market Drivers and Barriers
  34. Crohn’s Disease- Future Perspectives and Conclusion
  35. Crohn’s Disease Analyst Views
  36. Crohn’s Disease Key Companies
  37. Appendix

 

For further information on the Crohn’s Disease Pipeline therapeutics, reach out to Crohn’s Disease Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking